Impact of gender on baseline presentation and outcome in adult IgA vasculitis.

IgA vasculitis female gender male prognostic sex vasculitis

Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
04 Dec 2023
Historique:
received: 13 06 2023
revised: 18 10 2023
accepted: 08 11 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: aheadofprint

Résumé

Adult IgA vasculitis (IgAV) is more common in males, but the potential impact of gender remains unclear. We aimed to describe the impact of gender on presentation and outcome in adult IgAV. We retrospectively analysed data from a multicentre retrospective cohort of 260 patients (IGAVAS). Comparisons were made according to gender status. Data from 259 patients (95 females and 164 males) were analysed. Compared with females, baseline presentation in males was similar for cutaneous involvement (100% vs 100%, p= 1.0), joint involvement (60% vs 63%, p= 0.7), gastrointestinal involvement (57% vs 45%, p= 0.093) and glomerulonephritis (73% vs 64%, p= 0.16). Glomerulonephritis was more severe at baseline in males than in females, with a lower median estimated glomerular filtration rate (eGFR) (90 [IQR 59-105] vs 97 ml/min/1.73m2 [76-116], p= 0.015) and increased median proteinuria (0.84 vs 0.58 g/day, p= 0.01). There were no differences in histological findings in patients who had a kidney biopsy. Methylprednisolone was more frequently used in males (40% vs22%, p= 0.015), as were immunosuppressants, especially cyclophosphamide 24% vs 6%, p= 0.0025) and azathioprine (10% vs 2%, p= 0.038). Analysis of treatment response showed that males had more frequent refractory disease (30% vs 13%, p= 0.004). Long-term outcomes (mortality and progression to chronic kidney failure) did not differ. Kidney involvement in IgAV appears to more severe in males, which is supported by more intensive treatment contrasting with a lower response rate. This study raises the question of gender as a new prognostic factor in adult IgAV.

Identifiants

pubmed: 38048626
pii: 7458460
doi: 10.1093/rheumatology/kead648
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Kim-Liên Baud (KL)

Department of Internal Medicine, CHU de Tours, Tours, France.

Antoine Hankard (A)

Department of Internal Medicine, CHU de Caen, Caen, France.

Yanis Ramdani (Y)

Department of Internal Medicine, CHU de Tours, Tours, France.
University of Tours, Tours, France.

Valentin Maisons (V)

Department of Nephrology, CHU de Tours, Tours, France.

Evangeline Pillebout (E)

Department of Nephrology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Jean François Augusto (JF)

Department of Nephrology, CHU de Angers, Angers, France.

Noémie Jourde-Chiche (N)

Nephrology, Aix-Marseille Université, C2VN, INSERM, INRAE, AP-HM CHU Conception, Marseille, France.

Stanislas Faguer (S)

Department of Nephrology, CHU de Toulouse, Toulouse, France.

Nicole Ferreira-Maldent (N)

Department of Internal Medicine, CHU de Tours, Tours, France.

François Maillot (F)

Department of Internal Medicine, CHU de Tours, Tours, France.
University of Tours, Tours, France.

Jean-Michel Halimi (JM)

Department of Nephrology, CHU de Tours, Tours, France.
Department of Internal Medicine, CHU de Caen, Caen, France.

Benjamin Terrier (B)

Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin Paris, Paris, France.
Paris Cité University, Paris, F-75006, France.

Alexandra Audemard-Verger (A)

Department of Internal Medicine, CHU de Tours, Tours, France.
University of Tours, Tours, France.

Classifications MeSH